These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9413091)

  • 41. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130.
    Voss G; Dittmer U; Coulibaly C; Makoschey B; Petry H; Lüke W; Hunsmann G
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1757-63. PubMed ID: 8376957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunisation of macaques with SIV env recombinants: specificity of T cell and antibody responses and evaluation of protective efficacy.
    Mills KH; Page M; Kitchin P; Chan L; Jones W; Silvera P; Corcoran T; Flanagan B; Ling C; Thiriart C
    J Med Primatol; 1993; 22(2-3):104-9. PubMed ID: 8411102
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine.
    Arthur LO; Bess JW; Chertova EN; Rossio JL; Esser MT; Benveniste RE; Henderson LE; Lifson JD
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S311-9. PubMed ID: 9814959
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccine-induced CD4+ T cells against the simian immunodeficiency virus gag protein. Epitope specificity and relevance to protective immunity.
    Mills KH; Barnard AL; Williams M; Page M; Ling C; Stott EJ; Silvera P; Taffs F; Kingsman AS; Adams SE
    J Immunol; 1991 Nov; 147(10):3560-7. PubMed ID: 1719081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins.
    Lifson JD; Rossio JL; Piatak M; Bess J; Chertova E; Schneider DK; Coalter VJ; Poore B; Kiser RF; Imming RJ; Scarzello AJ; Henderson LE; Alvord WG; Hirsch VM; Benveniste RE; Arthur LO
    AIDS Res Hum Retroviruses; 2004 Jul; 20(7):772-87. PubMed ID: 15307924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.
    Amara RR; Smith JM; Staprans SI; Montefiori DC; Villinger F; Altman JD; O'Neil SP; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McNicholl JM; McClure HM; Moss B; Robinson HL
    J Virol; 2002 Jun; 76(12):6138-46. PubMed ID: 12021347
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of Three Types of Inactivation Agents on the Antibody Response and Immune Protection of Inactivated IHNV Vaccine in Rainbow Trout.
    Tang L; Kang H; Duan K; Guo M; Lian G; Wu Y; Li Y; Gao S; Jiang Y; Yin J; Liu M
    Viral Immunol; 2016 Sep; 29(7):430-5. PubMed ID: 27548006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
    Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M
    J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Construction of recombinant vaccinia virus expressing Rinderpest Virus nucleocapsid protein and its immunogenicity in mice.
    Ohishi K; Kamata H; Ohkubo S; Yamanouchi K; Kai C
    J Vet Med Sci; 1998 May; 60(5):655-6. PubMed ID: 9637306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.
    Doria-Rose NA; Ohlen C; Polacino P; Pierce CC; Hensel MT; Kuller L; Mulvania T; Anderson D; Greenberg PD; Hu SL; Haigwood NL
    J Virol; 2003 Nov; 77(21):11563-77. PubMed ID: 14557642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.
    Amara RR; Villinger F; Staprans SI; Altman JD; Montefiori DC; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McClure HM; Moss B; Robinson HL
    J Virol; 2002 Aug; 76(15):7625-31. PubMed ID: 12097576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
    Graham BS; Gorse GJ; Schwartz DH; Keefer MC; McElrath MJ; Matthews TJ; Wright PF; Belshe RB; Clements ML; Dolin R
    J Infect Dis; 1994 Oct; 170(4):782-6. PubMed ID: 7930718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.
    Collins PL; Purcell RH; London WT; Lawrence LA; Chanock RM; Murphy BR
    Vaccine; 1990 Apr; 8(2):164-8. PubMed ID: 2336876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recombinant-expressed virus-like particle pseudotypes as an approach to vaccine development.
    McGuigan LC; Stallard V; Roos JM; Payne LG
    Vaccine; 1993; 11(6):675-8. PubMed ID: 8322492
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of neutralizing antibodies against bovine leukosis virus in rabbits by vaccination with recombinant vaccinia virus expressing bovine leukosis virus envelope glycoprotein.
    Ohishi K; Suzuki H; Maruyama T; Yamamoto T; Funahashi S; Miki K; Ikawa Y; Sugimoto M
    Am J Vet Res; 1990 Aug; 51(8):1170-3. PubMed ID: 2167028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques.
    Mitchell WM; Torres J; Johnson PR; Hirsch V; Yilma T; Gardner MB; Robinson WE
    AIDS; 1995 Jan; 9(1):27-34. PubMed ID: 7893438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants.
    Gonzalo RM; Rodríguez D; García-Sastre A; Rodríguez JR; Palese P; Esteban M
    Vaccine; 1999 Feb; 17(7-8):887-92. PubMed ID: 10067695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.